Product Description
GMI-1687 is a highly potent antagonist of E-selectin from GlycoMimetics. (Sourced from: https://glycomimetics.com/pipeline/programs/gmi-1687/)
Mechanisms of Action: SELE Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlycoMimetics
Company Location: ROCKVILLE MD 20850
Company CEO: Harout Semerjian
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - GlycoMimetics presented P1 Healthy Volunteers results on 2024-01-04 for GMI-1687
Highest Development Phases
Phase 0: Acute Vasoocclusive Crisis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|